HC Wainwright Has Optimistic Outlook of SNDX FY2030 Earnings

Key Points

• HC Wainwright raised its FY2030 EPS estimate to $3.52 (from $3.16), a markedly more optimistic forecast compared with the current consensus full‑year EPS of -$1.65.
• In Q1 Syndax delivered an EPS beat (loss of $0.48 vs. -$0.59 expected) and revenue rose ~224% YoY to $64.9M—driven by Revuforj/revumenib (~$48.9M)—but revenue slightly missed estimates and the company remains unprofitable with negative margins and elevated leverage.
• Multiple brokers have raised ratings/targets (JPMorgan, Citi, Goldman, Barclays), leaving Syndax with a consensus "Moderate Buy" and a $40.50 target, while institutional ownership (e.g., Vanguard, Elmind) has increased materially.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Equities researchers at HC Wainwright increased their FY2030 EPS estimates for Syndax Pharmaceuticals in a note issued to investors on Friday, May 1st. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of $3.52 per share for the year, up from their prior forecast of $3.16. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($1.65) per share.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.11. Syndax Pharmaceuticals had a negative net margin of 111.88% and a negative return on equity of 216.23%. The company had revenue of $64.86 million during the quarter, compared to the consensus estimate of $69.76 million. During the same period in the previous year, the firm earned ($0.98) earnings per share. Syndax Pharmaceuticals's revenue for the quarter was up 224.3% on a year-over-year basis.

A number of other brokerages have also recently weighed in on SNDX. JPMorgan Chase & Co. upped their price target on shares of Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an "overweight" rating in a research report on Monday, March 9th. Citigroup boosted their price objective on Syndax Pharmaceuticals from $51.00 to $57.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Jefferies Financial Group reaffirmed a "buy" rating and issued a $40.00 target price (down from $48.00) on shares of Syndax Pharmaceuticals in a research report on Monday, March 30th. The Goldman Sachs Group increased their target price on Syndax Pharmaceuticals from $28.00 to $34.00 and gave the company a "buy" rating in a research note on Wednesday, April 1st. Finally, Wall Street Zen upgraded Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, March 8th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $40.50.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $19.08 on Monday. The company has a current ratio of 4.40, a quick ratio of 4.12 and a debt-to-equity ratio of 5.32. The company has a market cap of $1.68 billion, a PE ratio of -6.84 and a beta of 0.41. The company's fifty day simple moving average is $23.03 and its 200-day simple moving average is $20.43. Syndax Pharmaceuticals has a 52 week low of $8.58 and a 52 week high of $25.59.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Elmind Capital LP acquired a new stake in Syndax Pharmaceuticals during the 4th quarter valued at approximately $38,974,000. Vanguard Group Inc. increased its holdings in Syndax Pharmaceuticals by 21.2% during the 4th quarter. Vanguard Group Inc. now owns 6,230,334 shares of the company's stock worth $130,899,000 after purchasing an additional 1,091,717 shares during the last quarter. Bank of America Corp DE raised its position in shares of Syndax Pharmaceuticals by 33.7% in the 2nd quarter. Bank of America Corp DE now owns 3,838,872 shares of the company's stock valued at $35,951,000 after purchasing an additional 967,873 shares in the last quarter. Qube Research & Technologies Ltd raised its position in shares of Syndax Pharmaceuticals by 99.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,665,916 shares of the company's stock valued at $15,601,000 after purchasing an additional 831,067 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Syndax Pharmaceuticals by 126.8% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,432,440 shares of the company's stock valued at $13,415,000 after buying an additional 800,800 shares during the last quarter.

Insiders Place Their Bets

In related news, CFO Keith A. Goldan sold 3,410 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 9th. The shares were sold at an average price of $21.03, for a total transaction of $71,712.30. Following the sale, the chief financial officer owned 140,429 shares of the company's stock, valued at $2,953,221.87. The trade was a 2.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Michael A. Metzger sold 17,159 shares of the business's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $21.03, for a total transaction of $360,853.77. Following the completion of the transaction, the chief executive officer owned 491,690 shares in the company, valued at $10,340,240.70. This represents a 3.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 30,063 shares of company stock valued at $628,332. Company insiders own 4.10% of the company's stock.

Syndax Pharmaceuticals News Roundup

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Barclays raised its price target to $37 and upgraded SNDX to "overweight," implying large upside versus the current price — a bullish analyst endorsement that can support the stock. Barclays Raises Price Target
• Positive Sentiment: Commercial traction: management reported strong product sales (Revuforj/revumenib net revenue ~$48.9M) and collaboration revenue tied to Niktimvo, driving total revenue up ~224% YoY — and the company highlighted upcoming real‑world/frontline data in 2Q26 and Phase 2 topline readouts in 4Q26 (near-term catalysts). Syndax Q1 Results & Business Update
• Positive Sentiment: Earnings per share beat: reported loss of $0.48 vs. consensus loss of $0.59 — an improvement from last year and a metric that can temper downside from the revenue miss. Q1 EPS Beat Summary
• Neutral Sentiment: Earnings call transcript and slide deck are available for investors who want management color on commercial uptake and pipeline timelines. Earnings Call Transcript
• Neutral Sentiment: Quick analyst/press snapshots are circulating summarizing Q1 results and the conference call; useful for catching detail but less likely to move the stock alone. Q1 Earnings Snapshot
• Negative Sentiment: Revenue missed consensus ($64.9M reported vs. ~$69.8M expected), and the company still shows negative net margin/ROE and elevated leverage metrics noted in public filings — these mixed fundamentals likely pressured the stock despite the EPS beat and analyst upgrade. Revenue Miss & Financial Metrics

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax's research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company's lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.